prifemilast   Click here for help

GtoPdb Ligand ID: 14653

Synonyms: COMPOUND I [WO2022005494] | HPP-737 | HPP737 | HY-1999
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Prifemilast (HPP737/HY-1999) is an orally bioavailable phosphodiesterase 4 (PDE4) inhibitor [1]. It is designed for reduced CNS permeability compared to roflumilast, to reduce the risk of adverse psychiatric disorder effects. Note that we show the structure with the stereochemistry as defined in the INN record, and in [1]. PubChem CID 155670934 shows the structure without the absolute stereo.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 99.51
Molecular weight 479.91
XLogP 1.41
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC1=C2C(=CC=C1)C3=C(C=N2)C(=O)N([C@H]4CC[C@@H](CC4)C(=O)O)C(=O)N3C5=CC(=CC=C5)Cl
Isomeric SMILES O=C1N(C2=C3C(C(OC)=CC=C3)=NC=C2C(=O)N1[C@@H]4CC[C@@H](C(O)=O)CC4)C5=CC(Cl)=CC=C5
InChI InChI=1S/C25H22ClN3O5/c1-34-20-7-3-6-18-21(20)27-13-19-22(18)28(17-5-2-4-15(26)12-17)25(33)29(23(19)30)16-10-8-14(9-11-16)24(31)32/h2-7,12-14,16H,8-11H2,1H3,(H,31,32)/t14-,16-
InChI Key SMGRCNCCYFMFAP-KOMQPUFPSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Prifemilast (HPP737) was progressed as a clinical candidate, as a novel anti-inflammatory agent [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07712705 HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis. Phase 3 Interventional Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
NCT07712731 HPP737 in Adult Patients With Plaque Psoriasis Phase 3 Interventional Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
NCT04714294 Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1 Interventional Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. 2